Stabilized Guanylate Cyclase C Peptide Formulations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peptide formulations for guanylate cyclase C agonists face challenges with chemical and physical instability, leading to ineffective treatment options for gastrointestinal disorders such as irritable bowel syndrome and inflammatory bowel disease, particularly due to degradation mechanisms in human intestinal and gastric juices.
Innovation Solution
Development of low-dose, stabilized formulations of guanylate cyclase C peptide agonists using analogs of uroguanylin and bacterial ST peptides, combined with pharmaceutically acceptable excipients like mannitol and divalent cation salts, which provide resistance to degradation and improved chromatographic purity, stability, and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional peptide formulations are used, then the formulations can be administered, but they suffer from chemical and physical instability leading to degradation in intestinal and gastric juices
Solution Approach 1:
The patent employs protective excipients and formulation strategies that act as intermediaries between the peptide agonist and the harsh gastrointestinal environment. These intermediaries protect the peptide from degradation by enzymes and harsh pH conditions, thereby resolving the contradiction between administerability and stability.
Solution Approach 2:
The patent modifies physical and chemical parameters of the formulation, including pH adjustment, use of stabilizing agents, and controlled release mechanisms, to enhance peptide stability in the gastrointestinal tract while maintaining its therapeutic efficacy.
2Reliability
If higher doses are used to overcome degradation, then efficacy might be maintained, but the dosage exceeds the unexpectedly low effective range in humans
Solution Approach 1:
The patent converts the previously harmful degradation into a benefit by developing formulations that are specifically designed to withstand gastrointestinal conditions. This allows the use of low doses that were previously thought to be ineffective, thereby resolving the contradiction between efficacy and dosage quantity.
Solution Approach 2:
By optimizing formulation parameters such as peptide analog structure, excipient composition, and delivery system characteristics, the patent achieves enhanced stability and efficacy at unexpectedly low dosage levels, resolving the contradiction between maintaining efficacy and reducing dosage.
3Stability of the object's composition
If peptide analogs with improved stability are developed, then resistance to degradation increases, but the formulation complexity increases
Solution Approach 1:
The patent extracts and addresses the specific degradation mechanisms affecting peptide agonists by incorporating targeted protective excipients and formulation strategies. This selective approach enhances stability without unnecessarily complicating the overall formulation, resolving the contradiction between degradation resistance and formulation complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations demonstrate unexpected efficacy in humans with a lower dosage range than predicted, offering effective treatment and prevention of gastrointestinal disorders like chronic idiopathic constipation, Crohn's disease, and ulcerative colitis, with enhanced resistance to degradation and improved stability.
Implementation Method 1
the GCC agonist peptide is stabilized against chemical degradation
Implementation Method 2
resistance to degradation and improved stability
Data Source
AI summary
The invention provides low-dose formulations of guanylate cyclase-C (“GCC”) agonist peptides and methods for their use. The formulations of the invention can be administered either alone or in combination with one or more additional therapeutic agents, preferably an inhibitor of cGMP-dependent phosphodiesterase or a laxative.